PLX

Business Context and Reporting Period

Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: Protalix is a biopharmaceutical company developing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The lead product candidate is taliglucerase alfa for the treatment of Gaucher disease. The company operates primarily through its Israeli subsidiary, Protalix Ltd.

Key Financial Metrics

Liquidity: The company reported a net increase in cash of $14.3 million for the quarter, driven primarily by financing activities. Management believes current cash resources are sufficient to fund operations for at least the next 12 months.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 262% to $4.1 million, primarily due to the recognition of revenue from products delivered to Pfizer under the license agreement and the completion of a short-term supply agreement with the Ministry of Health of Brazil. No products were shipped in Q1 2010.
• Collaboration Income: The company recorded $1.9 million in income from its collaboration with Pfizer (40% share of net profits from Brazil sales), compared to a $294,000 loss in the prior year.
• Operating Loss Reduction: Operating loss decreased to $5.0 million from $8.1 million year-over-year, despite higher R&D expenses, due to significant revenue recognition.
• Capital Raise: In March 2011, the company completed an underwritten public offering of 4 million shares, generating net proceeds of approximately $20.6 million.

Guidance, Outlook, and Risks

Regulatory Status (Critical Item)

On February 25, 2011, the FDA issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for taliglucerase alfa. The CRL indicated that the review was complete but questions remained precluding approval in its current form.

• Key Requests: The FDA requested additional data from the switchover trial and long-term extension trial (clinical section) and information regarding testing specifications and assay validation (CMC section).
• Management Response: The company believes it can address all requests within the next few months. No additional clinical studies were requested.
• Outlook: Approval is not guaranteed. Any additional requests or rejection would materially adversely affect the business.

Other Developments

• France: The company continues to supply taliglucerase alfa to patients in France under a Temporary Authorization for Use (ATU).
• Brazil: Discussions are ongoing regarding a potential long-term supply agreement with the Ministry of Health of Brazil, though no agreement is expected until marketing approval is received.
• Manufacturing: The company is expanding its manufacturing facility in Carmiel, Israel, with estimated total costs of $25 million.

Risk Factors

Key risks include delays in responding to the FDA CRL, potential rejection of the NDA, inability to secure additional financing, and the inherent uncertainties of clinical development and regulatory approval processes.

Investor Verification Checklist

• FDA CRL Response Timeline: Verify the company's progress in submitting the response to the FDA's Complete Response Letter and any subsequent communications from the FDA.
• Cash Burn Rate: Monitor quarterly cash usage to confirm the "12-month runway" assertion remains valid given the $25 million manufacturing expansion plan.
• Brazil Long-Term Agreement: Track the status of negotiations with the Brazilian Ministry of Health for a long-term supply deal.
• Deferred Revenue: Review the amortization schedule of the $60 million upfront payment from Pfizer to understand future revenue recognition patterns.
• Manufacturing Expansion: Assess capital expenditure progress and potential need for additional funding to complete the facility expansion.